Sonia Bains, MD
Allergy & Immunology · Raleigh, NCNPI 1265699243
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,359 of the $23,311 with a category attached, or 61.6%. 39 manufacturers reported payments, led by Pfizer at 26.8% of the total. Reporting peaked in 2019 at $10,624 and has fallen 78.0% since, to $2,341 in 2025.
Across 686 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- AstraZeneca$4K
- Biocryst Pharmaceuticals, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$2K
- CSL Behring$1K
- plus $6K from 33 others
What the payments were for
- Consulting fees$4602%
- Speaking & faculty fees$7,43032%
- Travel & lodging$7413%
- Food & beverage$14,35962%
- Education$3221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $6,242 |
| AstraZeneca | 82 | $3,573 |
| Biocryst Pharmaceuticals, Inc. | 8 | $2,950 |
| Regeneron Healthcare Solutions, Inc. | 73 | $1,822 |
| GSK | 85 | $1,640 |
| CSL Behring | 61 | $1,104 |
| Amgen | 75 | $1,005 |
| Sanofi | 29 | $694 |
| AbbVie | 31 | $508 |
| Novartis | 22 | $400 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $385 |
| Kaleo, Inc. | 20 | $312 |
| Biocryst US Sales Co., LLC | 14 | $300 |
| Genentech USA, Inc. | 14 | $233 |
| Alk-abello, Inc | 8 | $197 |
| Teva Pharmaceuticals USA, Inc. | 13 | $181 |
| Sanofi-aventis U.S. LLC | 2 | $175 |
| Optinose US, Inc. | 11 | $172 |
| Pharming Healthcare, Inc. | 8 | $156 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $156 |
| Covis Pharma GmbH | 9 | $140 |
| Grifols USA, LLC | 4 | $136 |
| LEO Pharma Inc. | 6 | $127 |
| Shire North American Group Inc | 2 | $102 |
| Abbott | 1 | $92 |
| Octapharma USA, Inc. | 2 | $89 |
| Aimmune Therapeutics, Inc. | 4 | $81 |
| Boehringer Ingelheim | 3 | $56 |
| Merck | 3 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $41 |
| Phadia US Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Greer Laboratories, Inc. | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Incyte Corporation | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,311 in reported general payments places this provider in the 80th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 22 | $66,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $54,494 |
| Dupixent SyringeDupilumab | 14 | $52,273 |
| Epinephrine | 44 | $7,770 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,385 |
| Arnuity ElliptaFluticasone Furoate | 11 | $5,357 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,052 |
| Montelukast Sodium | 29 | $443 |
| Azelastine Hcl | 15 | $433 |
| Fluticasone Propionate | 17 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $1,104 | $66,73222 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,640 | $66,23697 claims |
| Hikma Pharmaceuticals USAEpinephrine | $29 | $7,77044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Raleigh
- Karen DunnRaleigh$258K
- Jonathan RomeoRaleigh$230K
- Laurie McWilliamsRaleigh$85K
- Gurvinder DeogunRaleigh$14K
- Craig LaforceRaleigh$14K
- Maureen PetersenRaleigh$13K
- Heather GutekunstRaleigh$12K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.